Apigenin's Health Benefits in Kidney Disease: Pharmacological Insights and Future Perspectives
J Wu, W Dai, K Li, X Ding, H Gao… - Food Reviews …, 2024 - Taylor & Francis
The incidence of kidney diseases is increasing globally, posing a serious threat to human
health. Studies have shown that apigenin, a natural dietary flavonoid with multiple …
health. Studies have shown that apigenin, a natural dietary flavonoid with multiple …
Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN …
Background Primary tumor removal by cytoreductive nephrectomy in synchronous
metastatic renal cell carcinoma patients has been investigated in the context of various …
metastatic renal cell carcinoma patients has been investigated in the context of various …
Deciphering glutamine metabolism patterns for malignancy and tumor microenvironment in clear cell renal cell carcinoma
G Wu, T Li, Y Chen, S Ye, S Zhou, X Tian… - Clinical and …, 2024 - Springer
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer
characterized by metabolic reprogramming. Glutamine metabolism is pivotal in metabolic …
characterized by metabolic reprogramming. Glutamine metabolism is pivotal in metabolic …
KIDNEY-PAGER: analysis of circulating tumor DNA as a biomarker in renal cancer–an observational trial. Study protocol
L Iisager, J Ahrenfeldt, AK Keller, TK Nielsen… - Acta …, 2023 - pmc.ncbi.nlm.nih.gov
Background Management of localized renal cell carcinoma (RCC) is challenged by
inaccurate methods to assess the risk of recurrence and deferred detection of relapse and …
inaccurate methods to assess the risk of recurrence and deferred detection of relapse and …
Prognostic value of systemic immune-inflammation index in patients with metastatic renal cell carcinoma treated with systemic therapy: a meta-analysis
J Xu, P Chen, S Cao, X Hu, X Li - Frontiers in Oncology, 2024 - pmc.ncbi.nlm.nih.gov
Objective A novel systemic immune-inflammation index (SII), based on the neutrophils,
lymphocytes, and platelet counts, is associated with the prognosis of several cancers …
lymphocytes, and platelet counts, is associated with the prognosis of several cancers …
Challenges and Considerations in Modern Adjuvant Therapy Trials in Renal Cell Carcinoma: A Call to Power
DD Shapiro, P Msaouel - European urology, 2024 - pubmed.ncbi.nlm.nih.gov
Identification of effective adjuvant therapies for renal cell carcinoma remains challenging
despite the development of immune checkpoint inhibitors. Enhancement of the design of …
despite the development of immune checkpoint inhibitors. Enhancement of the design of …